Al-Dawaa Medical Services Company (4163.SR)
SAR 82.7
(-2.13%)
SAR 82.7
(-2.13%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.44 Billion SAR | -12.3% |
| 2022 | 1.65 Billion SAR | 103.28% |
| 2021 | 812.3 Million SAR | 41.04% |
| 2020 | 575.95 Million SAR | -2.01% |
| 2019 | 587.77 Million SAR | 1.39% |
| 2018 | 579.73 Million SAR | -9.1% |
| 2017 | 637.77 Million SAR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.4 Billion SAR | -30.56% |
| 2024 Q2 | 1.37 Billion SAR | -44.02% |
| 2023 Q4 | 1.44 Billion SAR | 2.97% |
| 2023 FY | 1.44 Billion SAR | -12.3% |
| 2023 Q3 | 1.4 Billion SAR | -4.9% |
| 2023 Q2 | 1.47 Billion SAR | -6.18% |
| 2023 Q1 | 1.57 Billion SAR | -4.54% |
| 2022 Q2 | 1.59 Billion SAR | 91.51% |
| 2022 FY | 1.65 Billion SAR | 103.28% |
| 2022 Q4 | 1.65 Billion SAR | -9.22% |
| 2022 Q3 | 1.81 Billion SAR | 13.82% |
| 2022 Q1 | 834.49 Million SAR | 2.73% |
| 2021 Q1 | - SAR | -100.0% |
| 2021 FY | 812.3 Million SAR | 41.04% |
| 2021 Q4 | 812.3 Million SAR | 0.0% |
| 2021 Q2 | 689.74 Million SAR | 0.0% |
| 2020 Q1 | - SAR | 0.0% |
| 2020 Q3 | 575.95 Million SAR | 0.0% |
| 2020 Q4 | 575.95 Million SAR | 0.0% |
| 2020 FY | 575.95 Million SAR | -2.01% |
| 2019 FY | 587.77 Million SAR | 1.39% |
| 2018 FY | 579.73 Million SAR | -9.1% |
| 2017 FY | 637.77 Million SAR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 3.16 Million SAR | -45596.19% |
| Nahdi Medical Company | 870.56 Million SAR | -66.34% |
| Al-Razi Medical Co. | 1.77 Million SAR | -81477.084% |
| Almujtama Alraida Medical Co. | - SAR | -Infinity% |